Stockscreener 앱 받기
0.1995
3.72%
0.0032
전일 마감가:
$0.1963
열려 있는:
$0.197
하루 거래량:
13,337
Relative Volume:
0.04
시가총액:
$13.43M
수익:
$598.00K
순이익/손실:
$-44.93M
주가수익비율:
-0.024
EPS:
-8.31
순현금흐름:
$-17.32M
1주 성능:
-5.74%
1개월 성능:
+6.60%
6개월 성능:
-80.42%
1년 성능:
-88.09%
1일 변동 폭
$0.197
$0.2066
1주일 범위
$0.1917
$0.23
52주 변동 폭
$0.1506
$2.625
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
명칭
Ernexa Therapeutics Inc
전화
(212) 582-1199
주소
1035 CAMBRIDGE STREET, CAMBRIDGE
ERNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.1995 | 13.43M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.27 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.12 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
650.98 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.44 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.76 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) Declares $0.09 Monthly Dividend - MarketBeat
Eterna Therapeutics sets annual meeting date, opens nominations - MSN
Better AI Stock: SoundHound AI vs. Broadcom - The Globe and Mail
Eterna Therapeutics Hosts Successful Inaugural Meeting with - GlobeNewswire
Can Eterna's Expert-Backed Cell Therapy Breakthrough Revolutionize Ovarian Cancer Treatment? - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Eterna Therapeutics Inc (ERNA)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
Ratio Examination: Eterna Therapeutics Inc (ERNA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Ernexa Therapeutics Inc (ERNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
2.96%
자본화:
|
볼륨(24시간):